89 patents
Page 2 of 5
Utility
Easy-open peel pouch
26 Apr 22
Embodiments include a package for containing and dispensing a product.
Julie A. Cardin, Edward Emmett Chapdelaine, Steven A. Rau
Filed: 23 Sep 20
Utility
Modified Release Formulations and Uses Thereof
21 Apr 22
Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
Filed: 30 Sep 21
Utility
Salts of a Heterocyclic Compound and Crystalline Forms, Processes for Preparing, Therapeutic Uses, and Pharmaceutical Compositions Thereof
31 Mar 22
The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
Nandkumar Nivritti BHOGLE, Takahiko HASHIZUKA, Robert Joseph PRYTKO, John R. SNOONIAN, Harold Scott WILKINSON, Haitao ZHANG
Filed: 15 Jun 21
Utility
Methods of Treating Schizophrenia
3 Mar 22
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia.
Seth Hopkins, Kenneth Koblan, Antony Loebel, Ajay Ogirala
Filed: 6 Apr 21
Utility
Methods of Treating Central Nervous System Disorders
16 Dec 21
Provided herein are methods of treating central nervous system (CNS) disorders (e.g., Binge Eating Disorder (BED), Attention-Deficit/Hyperactivity Disorder (ADHD), etc.) with a dasotraline therapy while avoiding adverse drug interactions.
Jing LIN
Filed: 30 Oct 19
Utility
1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
7 Dec 21
Linghong Xie, Philip Glyn Jones, Kerry L. Spear, Noel Aaron Powell, Taleen G. Hanania, Vadim Alexandrov
Filed: 6 May 19
Utility
Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
30 Nov 21
Michele L. R. Heffernan, Larry Wendell Hardy, Scott P. Brown, Lee W. Herman
Filed: 4 Aug 16
Utility
Modified release formulations and uses thereof
2 Nov 21
Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Takumi Asada, Gerald R. Galluppi, Seth Cabot Hopkins, Megumi Maruyama, Siriporn Toongsuwan, Yuki Tsushima
Filed: 4 Jun 20
Utility
Sublingual Apomorphine
21 Oct 21
The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.
Anthony John GIOVINAZZO, David Bruce HEDDEN, Marc L. DE SOMER, Nathan John BRYSON
Filed: 26 Feb 21
Utility
Methods of Treating Neurological and Psychiatric Disorders
14 Oct 21
Carrie A. BOWEN, Seth Cabot HOPKINS, Colleen M. SYNAN
Filed: 13 Apr 21
Utility
Nonracemic Mixtures and Uses Thereof
14 Oct 21
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
Filed: 13 Nov 20
Utility
Methods of Treating a Patient Having Parkinson's Disease
14 Oct 21
Methods of treating a patient having Parkinson's disease, including treating “OFF” episodes and improving motor function, by administering apomorphine or a pharmaceutically acceptable salt thereof are disclosed herein.
Thierry BILBAULT, Bradford Armando NAVIA, Charles Warren OLANOW
Filed: 10 Jun 21
Utility
Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
5 Oct 21
The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
Nandkumar Nivritti Bhogle, Takahiko Hashizuka, Robert Joseph Prytko, John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
Filed: 13 Mar 20
Utility
Fused DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL Compounds and Analogs for Treating CNS Disorders
30 Sep 21
Milan CHYTIL, Sharon ENGEL, Taleen G. HANANIA, Vadim ALEXANDROV, Emer LEAHY
Filed: 19 Feb 21
Utility
Methods of treating schizophrenia
28 Sep 21
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia.
Seth Hopkins, Kenneth Koblan, Antony Loebel, Ajay Ogirala
Filed: 16 Feb 18
Utility
Multicyclic Compounds and Methods of Use Thereof
2 Sep 21
Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use.
Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
Filed: 19 Nov 20
Utility
Compounds and compositions and uses thereof
3 Aug 21
Vadim Alexandrov, Carrie A. Bowen, Taleen G. Hanania, Noel Aaron Powell
Filed: 28 Jul 17
Utility
Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
20 Jul 21
The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
Nandkumar Nivritti Bhogle, Takahiko Hashizuka, Robert Joseph Prytko, John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
Filed: 13 Mar 20
Utility
Methods of Treating Parkinson's Disease by Administration of Apomorphine to an Oral Mucosa
8 Jul 21
Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described.
Scott David BARNHART, Michael Clinton KOONS, Madhu Sudan HARIHARAN, Jordan DUBOW, Thierry BILBAULT, Anthony John GIOVINAZZO
Filed: 18 Feb 21
Utility
Acid Addition Salts of Apomorphine, Pharmaceutical Compositions Containing the Same, and Methods of Using the Same
17 Jun 21
Acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, and acid addition salt of apomorphine isobutyrate salts are disclosed.
Thierry BILBAULT
Filed: 22 Feb 21